Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1221239-09-3 | MDL No. : | MFCD18205310 |
Formula : | C15H20BNO3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | IAKVXXCASRMULQ-UHFFFAOYSA-N |
M.W : | 273.14 | Pubchem ID : | 53407631 |
Synonyms : |
|
Num. heavy atoms : | 20 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.53 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 82.78 |
TPSA : | 38.77 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | Yes |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.59 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.94 |
Log Po/w (WLOGP) : | 1.04 |
Log Po/w (MLOGP) : | 1.39 |
Log Po/w (SILICOS-IT) : | 1.67 |
Consensus Log Po/w : | 1.21 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.91 |
Solubility : | 0.335 mg/ml ; 0.00123 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.38 |
Solubility : | 1.14 mg/ml ; 0.00418 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.16 |
Solubility : | 0.0189 mg/ml ; 0.0000693 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 2.87 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
81% | With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate In N,N-dimethyl acetamide at 100℃; for 2h; Inert atmosphere; | 7-3 Preparation 7-1. 4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)-indan-l- one. General procedure: Preparation 7-1. 4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)-indan-l- one. [00122] To a solution of 4-bromo-l-indanone (1.0 g, 4.74 mmol) in N,N- dimethylacetamide (25 mL) was added bw(pinacolato)diboron (2.41 g, 9.48 mmol), 1,1 '- ^w(diphenylphosphino)ferrocene palladium(II) dichloride (346 mg, 0.47 mmol) and potassium acetate (1.40 g, 14.22 mmol) and the reaction mixture was stirred at 100 °C for 2 h under nitrogen. The mixture was evaporated and the residue was diluted with water (50 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by column chromatography eluting with hexane: ethyl acetate (100:0->4: 1) to give the title compound (1.8 g, 7.00 mmol, ca. 100%) as an off-white powder. LCMS: 97%, Rt 1.811 , ESMS m/z 259 (M+H-CH4)+. |
81% | With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate In N,N-dimethyl acetamide at 100℃; for 2h; Inert atmosphere; | 7-3 Preparation 7-1. 4-(4,4,5,5-Tetramethyl- 1,3 ,2-dioxaborolan-2-yl)-indan- 1-one. General procedure: To a solution of 4-bromo-l-indanone (1.0 g, 4.74 mmol) in N,Ndimethylacetamide (25 mL) was added bis(pinacolato)diboron (2.41 g, 9.48 mmol), 1,1’-bis(diphenylphosphino)ferrocene palladium(11) dichloride (346 mg, 0.47 mmol) and potassiumacetate (1.40 g, 14.22 mmol) and the reaction mixture was stirred at 100 °C for 2 h undernitrogen. The mixture was evaporated and the residue was diluted with water (50 mL) andextracted with dichloromethane (3 x 50 mL). The combined organic layers were dried oversodium sulfate and evaporated. The residue was purified by column chromatography eluting withhexane:ethyl acetate (100:0-4:1) to give the title compound (1.8 g, 7.00 mmol, Ca. 100%) as anoff-white powder. LCMS: 97%, Rt 1.811, ESMS m/z 259 (M+H-CH4). |
81% | With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate In N,N-dimethyl acetamide at 100℃; for 2h; Inert atmosphere; | 7-3 Preparation 7-1. 4-(4,4,5,5-Tetramethyl- 1 ,3,2-dioxaborolan-2-yI)-indan- 1-one. General procedure: [00116] To a solution of 4-bromo-1-indanone (1.0 g, 4.74 mmol) in N,Ndimethylacetamide (25 mL) was added bis(pinacolato)diboron (2.41 g, 9.48 mmol), 1,1’- bis(diphenylphosphino)ferrocene palladium(II) dichloride (346 mg, 0.47 mmol) and potassium acetate (1.40 g, 14.22 mmol) and the reaction mixture was stirred at 100 °C for 2 h under nitrogen. The mixture was evaporated and the residue was diluted with water (50 mL) and extracted with dichloromethane (3 x 50 mE). The combined organic layers were dried over sodium sulfate and evaporated. The residue was purified by column chromatography eluting with hexane:ethyl acetate (100:0-)4:1) to give the title compound (1.8 g, 7.00 mmol, Ca. 100%) as an off-white powder |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With (1,5-cyclooctadiene)(methoxy)iridium(I) dimer; 4,4'-di-tert-butyl-2,2'-bipyridine In para-xylene at 35℃; for 24h; Overall yield = 54 %Spectr.; regioselective reaction; |
[ 1313399-38-0 ]
2-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.94
[ 376584-62-2 ]
5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.92
[ 1004294-80-7 ]
6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.92
[ 935660-75-6 ]
N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide
Similarity: 0.86
[ 179117-44-3 ]
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
Similarity: 0.84
[ 1313399-38-0 ]
2-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.94
[ 376584-62-2 ]
5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.92
[ 1004294-80-7 ]
6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.92
[ 935660-75-6 ]
N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide
Similarity: 0.86
[ 179117-44-3 ]
4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
Similarity: 0.84
[ 1313399-38-0 ]
2-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.94
[ 376584-62-2 ]
5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.92
[ 1004294-80-7 ]
6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one
Similarity: 0.92
[ 1220696-38-7 ]
1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one
Similarity: 0.77
[ 893441-85-5 ]
6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one
Similarity: 0.76